Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Next Science Ltd ( (AU:NXS) ) has shared an announcement.
Next Science Limited has updated the market on a procedural change to its planned capital management, announcing that the payment date for its cash return of capital has been moved to 10 February 2026, with all other terms of the return unchanged. The adjustment comes as the company completes the post-sale process following the disposal of substantially all of its assets to OSARTIS GmbH and progresses towards delisting from the ASX, making the timing of capital returns a key focus for remaining shareholders.
The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited, formerly a medical technology company focused on anti-biofilm solutions, has sold substantially all of its assets, along with those of its wholly owned subsidiaries, to German firm OSARTIS GmbH, part of the Demetra group. Following this divestment, the company has applied to be removed from the official list of the ASX, signalling an effective wind-down of its previous operating structure and listed-company status.
Average Trading Volume: 556,356
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
For a thorough assessment of NXS stock, go to TipRanks’ Stock Analysis page.